Risk adjusted net present value: What is the current valuation of Tenaya Therapeutics’s TN-401?

TN-401 is a gene therapy commercialized by Tenaya Therapeutics, with a leading Phase I program in Cardiomyopathy.

How pharma giants like GSK and Bristol Myers are using tech to shape their future

(This story is from our new Health Tech newsletter. If you’d like to sign up, just click here.) SAN FRANCISCO — Pharma companies are increasingly

January 17, 2024

Can Residents Flourish? Managing Common Foot and Ankle Conditions

TTHealthWatch is a weekly podcast from Texas Tech. In it, Elizabeth Tracey, director of electronic media for Johns Hopkins Medicine in Baltimore, and Rick Lange,

December 24, 2023

Innovative approaches in polymer nanoparticle synthesis for RNA therapeutics

RNA therapy with polymer nanoparticles is considered a promising approach for the treatment of various illnesses.

July 15, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.